August 03, 2021
A Pennsylvania federal court has given its final approval to an $8.5 million settlement between Trevena Inc. and investors who say the biopharmaceutical company misled them about federal approvals for a morphine alternative.
June 29, 2021
A class believed to consist of thousands of Trevena investors asked a Pennsylvania federal judge on Monday to grant final approval of an $8.5 million settlement, which would resolve claims that the biopharmaceutical company misled investors about the approval prospects of a new intravenous painkiller.
August 31, 2020
A Pennsylvania federal judge ruled Friday that a bid by Trevena Inc. to dodge claims it misled investors about the approval prospects of a new intravenous painkiller was improperly based on confidential documents that were not a part of the complaint in the case.
October 03, 2019
Trevena Inc. said in a dismissal bid Wednesday that the investors accusing it of misleading them about interactions with regulators have "seriously misapprehen[ded]" the main document underlying their claims.
May 29, 2019
Block & Leviton LLP and Kaufman Coren & Ress LLP were named class counsel in litigation accusing Trevena Inc. of artificially inflating its share value, a Pennsylvania federal judge decided on Wednesday, citing careless errors made by an investor represented by rival attorneys.
March 21, 2019
Citing alleged misstatements made by an investor represented by rival attorneys, Block & Leviton LLP and Kaufman Coren & Ress LLP have urged a Pennsylvania federal judge to name them class counsel in litigation accusing Trevena Inc. of artificially inflating its share value.